Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.73 |
| ▸ | CA1 | P00915 | 6/20 | 0.73 |
| ▸ | CA2 | P00918 | 6/20 | 0.73 |
| ▸ | CA9 | Q16790 | 6/20 | 0.73 |
| ▸ | PTPRF | P10586 | 2/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | IDE | P14735 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18391007 | 1.00 | CA12 (0.73) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL6036966 | 1.00 | CA12 (0.73) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL565442 | 0.99 | CA12 (0.72) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL14253654 | 0.90 | CA12 (0.74) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL25374435 | 0.90 | CA12 (0.74) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL565441 | 0.90 | CA12 (0.74) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL19940249 | 0.88 | CA12 (0.74) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL21524959 | 0.88 | CA12 (0.78) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL18329586 | 0.88 | CA12 (0.74) | CA12CA1CA2CA9PTPRF | |
| SCHEMBL12059002 | 0.88 | CA12 (0.74) | CA12CA1CA2CA9PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| EP-2089026-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2008070552-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | NOVARTIS AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | CA12 3516/4885CA1 4190/4885CA2 4446/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | CA12 3441/4885CA1 2920/4885CA2 2092/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | CA12 3345/4885CA1 4092/4885CA2 4346/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CA12 2422/4885CA1 2202/4885CA2 1569/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | CA12 2944/4885CA1 2697/4885CA2 3633/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | CA12 1226/4885CA1 2890/4885CA2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.